Parametrica Management LTD Altimmune, Inc. Transaction History

Parametrica Management LTD

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$9.85 - $16.46 $429,962 - $718,495	-43,651 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$12.71 - $24.31 $289,444 - $553,611	22,773 Added 109.08%	43,651 $591,000
Q4 2020 Feb 16, 2021	BUY	$7.84 - $14.22 $163,683 - $296,885	20,878 New	20,878 $236,000

185

44.4M

1.1M

647K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $324M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Parametrica Management LTD, based on Form 13F filings with the SEC.

Stay updated on Parametrica Management LTD with notifications on news.